A detailed history of Mackenzie Financial Corp transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 17,616 shares of PSTX stock, worth $56,547. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,616
Previous 17,616 -0.0%
Holding current value
$56,547
Previous $51,000 1.96%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.0 - $3.46 $35,232 - $60,951
17,616 New
17,616 $51,000
Q4 2023

Jan 30, 2024

SELL
$1.83 - $3.51 $4,392 - $8,424
-2,400 Reduced 15.08%
13,514 $45,000
Q3 2023

Oct 25, 2023

SELL
$1.62 - $2.79 $4,727 - $8,141
-2,918 Reduced 15.49%
15,914 $37,000
Q2 2023

Aug 03, 2023

BUY
$1.66 - $3.4 $31,261 - $64,028
18,832 New
18,832 $33,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $275M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.